Anebulo Pharmaceuticals (ANEB) Cash & Equivalents (2020 - 2025)

Anebulo Pharmaceuticals (ANEB) has reported Cash & Equivalents for 6 consecutive years, with $9.0 million the latest figure, recorded in Q4 2025.

• In Q4 2025, Cash & Equivalents fell 39.72% year-over-year to $9.0 million; the TTM figure through Dec 2025 stood at $9.0 million (down 39.72% YoY), while the FY2025 annual figure was $11.6 million, up 275.8% from the prior year.
• Cash & Equivalents eased to $9.0 million in Q4 2025 per ANEB's latest filing, from $10.4 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $20.0 million in Q2 2021 and bottomed at $1.4 million in Q3 2024.
• Historically, Cash & Equivalents has averaged $11.8 million across 5 years, with a median of $12.5 million in 2025.
• Annual changes were most pronounced in 2024 — Cash & Equivalents slumped 83.52% — and 2025, when it soared 637.41%.
• Anebulo Pharmaceuticals' Cash & Equivalents stood at $18.0 million in 2021, then dropped by 9.18% to $16.4 million in 2022, then plunged by 59.37% to $6.6 million in 2023, then jumped by 125.73% to $15.0 million in 2024, then slumped by 39.72% to $9.0 million in 2025.
• Business Quant data shows ANEB's Cash & Equivalents at $9.0 million in Q4 2025, $10.4 million in Q3 2025, and $11.6 million in Q2 2025.